In today’s briefing:
- Henlius (2696 HK): This Should Trade Tighter. Get Involved
- Quiddity Leaderboard STAR 50/100 Mar25: Multiple Changes, Large Flows; High-Impact Trade Idea
- Tempus AI: Initiation Of Coverage – Expansion in Minimal Residual Disease (MRD) Testing & 4 Other Factors That Could Shape Its Future! – Major Drivers
- MIRA: IND Application Submitted to FDA
Henlius (2696 HK): This Should Trade Tighter. Get Involved
- After the China Traditional Chinese Medicine (570 HK) fiasco back in October, Hong Kong M&As have received some welcome Xmas cheer of late.
- Small-Cap CM Hi-Tech (2115 HK) secured reg approvals in record time. Then CPMC (906 HK)‘s pre-cons were satisfied on 13th December. Now Shanghai Henlius (2696 HK)‘s pre-cons are also fulfilled.
- Henlius’ spread narrowed after securing NDRC approval on the 22nd Nov; and again after fulfilling pre-cons this week. A 3.1% gross spread is okay. This is done. Get involved.
Quiddity Leaderboard STAR 50/100 Mar25: Multiple Changes, Large Flows; High-Impact Trade Idea
- STAR 50 Index is a tech-focused, blue-chip index in Mainland China which tracks the top 50 largest and most liquid names in the STAR market of the Shanghai Stock Exchange.
- STAR 100 index tracks the next 100 names (51st-150th ranks) and it represents the mid-cap segment of the STAR market.
- In this insight, we look at the potential ADDs/DELs for the STAR50/STAR100 indices for the March 2025 index rebal event and suggest a high impact trade idea.
Tempus AI: Initiation Of Coverage – Expansion in Minimal Residual Disease (MRD) Testing & 4 Other Factors That Could Shape Its Future! – Major Drivers
- Tempus AI reported its third-quarter 2024 financial results, reflecting positive revenue growth but continuing to face profitability challenges.
- Revenue rose by 33%, reaching $180.9 million, driven by growth in the Genomics and Data and Services segments.
- Notably, the Genomics unit growth accelerated to 23.9%, which shows a significant uptick from the previous quarter.
MIRA: IND Application Submitted to FDA
- MIRA Pharmaceuticals(MIRA) Company Sponsored Research Report
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
